Premium
THE EFFECTS OF NAFARELIN AND DANAZOL ON VERTEBRAL TRABECULAR BONE MASS IN PATIENTS WITH ENDOMETRIOSIS
Author(s) -
WHITEHOUSE R. W.,
ADAMS J. E.,
BANCROFT K.,
VAUGHANWILLIAMS C. A.,
ELSTEIN M.
Publication year - 1990
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1990.tb00501.x
Subject(s) - danazol , bone mineral , medicine , endocrinology , bone mineral content , quantitative computed tomography , endometriosis , dual energy , bone mass , urology , osteoporosis
SUMMARY Single and dual‐energy quantitative computed tomography (QCT) were used to measure spinal trabecular bone mineral content in 24 women treated with either nafarelin (15 patients) or danazol (nine patients) for endometriosis. Significant loss of bone mineral (‐ 9.6 g/l; ‐ 5.9% P <0.001) was demonstrated after 6 months’treatment with nafarelin. This loss was reversible with no significant difference in the bone mineral measurement made before treatment and that made at 6 months after treatment was stopped (difference ‐ 1.95 g/l, NS). A small but statistically significant (+ 2.2 g/l, P<0.05) increase in bone mineral was measured in the group of patients treated with danazol for 6 months. The dual‐energy QCT gave similar results, indicating little change in trabecular fat content. A significant correlation was demonstrated between mean serum oestradiol levels during treatment with nafarelin and the change in bone mineral ( r = 0.655, P < 0.005).